Thermo Fisher Scientific Inc. $TMO Stake Cut by Legacy Private Trust Co.

Key Points

• Legacy Private Trust Co. reduced its stake in Thermo Fisher Scientific by 4.8%, holding 11,093 shares worth approximately $4.5 million after selling 556 shares in the second quarter.
• Thermo Fisher reported an EPS of $5.36 for Q2, exceeding expectations, with revenues of $10.86 billion, reflecting a 2.9% year-over-year increase.
• The company declared a quarterly dividend of $0.43 per share, with the next payment scheduled for October 15th, marking an annualized yield of 0.4%.

Legacy Private Trust Co. trimmed its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 4.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 11,093 shares of the medical research company's stock after selling 556 shares during the quarter. Legacy Private Trust Co.'s holdings in Thermo Fisher Scientific were worth $4,498,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of TMO. Bernard Wealth Management Corp. acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at $25,000. CBIZ Investment Advisory Services LLC grew its holdings in shares of Thermo Fisher Scientific by 137.5% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after acquiring an additional 33 shares during the last quarter. Ameriflex Group Inc. purchased a new position in Thermo Fisher Scientific in the 4th quarter worth about $30,000. Anderson Financial Strategies LLC purchased a new stake in Thermo Fisher Scientific during the first quarter valued at about $30,000. Finally, Keystone Global Partners LLC acquired a new stake in shares of Thermo Fisher Scientific during the first quarter valued at approximately $31,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Down 2.4%

NYSE:TMO opened at $479.48 on Monday. The company's 50 day moving average is $466.86 and its 200-day moving average is $450.58. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $623.77. The firm has a market cap of $181.06 billion, a price-to-earnings ratio of 27.73, a P/E/G ratio of 2.56 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same period last year, the business posted $5.37 EPS. Thermo Fisher Scientific's revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is presently 9.95%.

Insiders Place Their Bets

In other news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock valued at $14,182,963 in the last three months. Company insiders own 0.33% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on TMO. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the company an "outperform" rating in a report on Tuesday, September 2nd. William Blair initiated coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They set an "outperform" rating for the company. HSBC reissued a "hold" rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, September 7th. Finally, Barclays raised shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and upped their price target for the stock from $490.00 to $550.00 in a research note on Thursday. Seventeen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $592.24.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.